Ram Mukunda

EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses
Cannabis Based Pain Relief Solution Receives European Patent Approval
IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses
Cannabis Based Pain Relief Solution Receives European Patent Approval
THC-Based Alzheimer's Trial In Puerto Rico: IGC Pharma Targets Underrepresented Hispanic Communities
IGC Pharma FY23 Revenue Grows 129%, What About Net Loss?

Ram Mukunda Recent News

IGC Starts Phase 2 Clinical Trials Of THC Based Drug Candidate For The Treatment Of Agitation In Dementia From Alzheimer's Disease
India Globalization Capital, Inc. (AMEX:IGC) has begun “A phase 2, multi-center, double-blind, randomized, placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease”.
IGC Q2 2023 Revenue Grows 261%, THC Based Drug For Alzheimer's Entering Phase 2 Trials
India Globalization Capital, Inc. (AMEX:IGC) reported its second fiscal quarter 2023 financial results, revealing revenue of $202,000, a 261% increase compared to $56,000 in the same quarter of 2022.
Marijuana Could Help Treat Alzheimer's: Here's How It Would Work
Getting Into The Business Of Medical Marijuana: An Interview With IGC CEO Ram Mukunda
Trump, Sessions, Spicer And Medical Marijuana: Industry Insiders Discuss The Future Of Cannabis